CN115867281A - 治疗肺纤维化的方法 - Google Patents

治疗肺纤维化的方法 Download PDF

Info

Publication number
CN115867281A
CN115867281A CN202180038818.0A CN202180038818A CN115867281A CN 115867281 A CN115867281 A CN 115867281A CN 202180038818 A CN202180038818 A CN 202180038818A CN 115867281 A CN115867281 A CN 115867281A
Authority
CN
China
Prior art keywords
pulmonary fibrosis
formula
compound
acid
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180038818.0A
Other languages
English (en)
Chinese (zh)
Inventor
C·伯恩斯
J·兰伯特
M·G·德夫林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anpriya Treatment Co ltd
Original Assignee
Anpriya Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901743A external-priority patent/AU2020901743A0/en
Application filed by Anpriya Treatment Co ltd filed Critical Anpriya Treatment Co ltd
Publication of CN115867281A publication Critical patent/CN115867281A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180038818.0A 2020-05-28 2021-05-17 治疗肺纤维化的方法 Pending CN115867281A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020901743 2020-05-28
AU2020901743A AU2020901743A0 (en) 2020-05-28 Methods of treating pulmonary fibrosis
PCT/AU2021/050457 WO2021237273A1 (en) 2020-05-28 2021-05-17 Methods of treating pulmonary fibrosis

Publications (1)

Publication Number Publication Date
CN115867281A true CN115867281A (zh) 2023-03-28

Family

ID=78745664

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180038818.0A Pending CN115867281A (zh) 2020-05-28 2021-05-17 治疗肺纤维化的方法

Country Status (9)

Country Link
US (1) US20230190746A1 (https=)
EP (1) EP4157278A4 (https=)
JP (1) JP7745571B2 (https=)
KR (1) KR20230017843A (https=)
CN (1) CN115867281A (https=)
AU (1) AU2021279205B2 (https=)
CA (1) CA3177652A1 (https=)
NZ (1) NZ793855A (https=)
WO (1) WO2021237273A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3001119T3 (es) 2019-03-28 2025-03-04 Amplia Therapeutics Ltd Una sal y forma cristalina de un inhibidor de FAK
WO2023139154A1 (en) * 2022-01-19 2023-07-27 Nordic Bioscience A/S A method for detecting covid-19 in a patient

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103534240A (zh) * 2011-02-17 2014-01-22 癌症疗法Crc私人有限公司 选择性fak抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014027199A1 (en) * 2012-08-14 2014-02-20 Cancer Therapeutics Crc Pty Ltd Fak and flt3 inhibitors
ES3001119T3 (es) * 2019-03-28 2025-03-04 Amplia Therapeutics Ltd Una sal y forma cristalina de un inhibidor de FAK

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103534240A (zh) * 2011-02-17 2014-01-22 癌症疗法Crc私人有限公司 选择性fak抑制剂

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"CAS Registry Number：1393653-34-3", pages 1, Retrieved from the Internet <URL:STN REGISTRY> *
JOANA CARVALHO: "FDA Names AMP 945, Potential IPF Treatment, an Orphan Drug", pages 2, Retrieved from the Internet <URL:https://pulmonaryfibrosisnews.com/news/fda-names-amp945-potential-idiopathic-pf-treatment-orphan-drug/> *
JOANA CARVALHO: "FDA Names AMP945, Potential IPF Treatment, an Orphan Drug", pages 2, Retrieved from the Internet <URL:https://pulmonaryfibrosisnews.com/news/fda-names-amp945-potential-idiopathic-pf-treatment-orphan-drug/> *
PETER M GEORGE等: "Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy", 《LANCET RESPIR MED》, vol. 8, no. 8, 15 May 2020 (2020-05-15), pages 810 *
无: "ASX Release-FDA Awards Amplia Orphan Drug Designation for Idiopathic Pulmonary Fibrosis", pages 1, Retrieved from the Internet <URL:https://announcements.asx.com.au/asxpdf/20200519/pdf/44hyggg8s92tcq.pdf> *

Also Published As

Publication number Publication date
JP7745571B2 (ja) 2025-09-29
US20230190746A1 (en) 2023-06-22
WO2021237273A1 (en) 2021-12-02
KR20230017843A (ko) 2023-02-06
NZ793855A (en) 2026-02-27
EP4157278A4 (en) 2024-07-03
EP4157278A1 (en) 2023-04-05
AU2021279205A1 (en) 2022-12-08
JP2023527358A (ja) 2023-06-28
AU2021279205B2 (en) 2025-12-04
CA3177652A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
EP1933833B1 (en) Therapy for the treatment of overactive bladder
US20240197739A1 (en) Combination Comprising Ribociclib and Amcenestrant
US12427142B2 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
US8088827B2 (en) Use of irbesartan for the preparation of medicinal products that are useful for treating pulmonary hypertension
CN115867281A (zh) 治疗肺纤维化的方法
JP2003520237A (ja) 鬱病及び関連疾患を治療するためのミルトラザピン及びジェピロンを含有する配合剤
JP7854206B2 (ja) 肺線維症の予防または治療用の薬学製剤
CN110573148A (zh) 特发性肺纤维化的治疗
US8415390B2 (en) Methods and compositions for administration of oxybutynin
US8648100B2 (en) Roflumilast for the treatment of pulmonary hypertension
AU2012253667B2 (en) Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
EA009935B1 (ru) Новая синергетическая комбинация, включающая рофлумиласт и формотерол
JP2024534156A (ja) Ｎｕｒｒ１アゴニストの、アルドステロンアンタゴニスト、インスリンモジュレーター及びスルホニル尿素のうちの少なくとも１つとの組合せ
AU2008257319B2 (en) Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas
CN116723836A (zh) 用于治疗急性心房颤动的舒欣啶施用
KR20150051493A (ko) 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관신생 관련 질환의 예방 또는 치료용 약학적 조성물
WO2005063253A1 (ja) アレルギー症状治療用医薬組成物
TW202308623A (zh) 用於預防或治療纖維化之醫藥組成物
AU2021228371A1 (en) S1P receptor modulators
CN119522109A (zh) 用于钙调磷酸酶抑制剂的间歇性给药的组合物
US20040006142A1 (en) Ocular tension depressor
HK1221913B (zh) Par-1拮抗剂用於预防和/或治疗骨盆-会阴功能病状的用途
HK1232781A1 (en) Combinations of solifenacin and pilocarpine for the treatment of overactive bladder
HK1232781A (en) Combinations of solifenacin and pilocarpine for the treatment of overactive bladder
EP0998923A1 (en) Use of 5-HT7 receptor agonists for the treatment or prophylaxis of ischemias

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Australia

Address after: Australia Melbourne

Applicant after: Anpriya Treatment Private Ltd.

Address before: Australia Melbourne

Applicant before: Anpriya treatment Co.,Ltd.

Country or region before: Australia

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250226

Address after: Australia Melbourne

Applicant after: Anpriya treatment Co.,Ltd.

Country or region after: Australia

Address before: Australia Melbourne

Applicant before: Anpriya Treatment Private Ltd.

Country or region before: Australia